DYRK1A overexpression varies based on tissue and age (HAWLEY et al. 2023; LACOMBE et al. 2024), which means treating cognitive deficits could worsen bone, as evidenced by previous EGCG treatments (JAMAL et al. 2022). The gene discussed is DYRK1A; the disease is Cognitive impairment.